Successful First-in-Human Use of BENDIT21 Neurovascular Catheter Performed at the University of Texas Southwestern Medical Center

BENDIT Technologies, a company focused on the development of steerable microcatheters, announced today the successful first use in the USA of the BENDIT21 neuro catheter in a life-saving treatment. The case involved a 57-year-old female patient who had been suffering for years from an inoperable symptomatic internal carotid artery aneurysm.

The BENDIT steerable microcatheter is designed to allow access to hard-to-reach vasculature locations due to its three-dimensional clinician-controlled movement and independent control of catheter tip deflection. These advanced capabilities are intended to enable surgeons to navigate quickly and precisely through the neuro, peripheral and coronary vasculature.

Dr. John Barr, Professor of Radiology and Neurological Surgery, UT Southwestern Medical Center, used the BENDIT21 steerable microcatheter under compassionate use granted by the FDA.

“We were pleased to be granted FDA approval for the compassionate use for this first case in the U.S. Previous access attempts had failed both here at UT Southwestern and at an outside facility because the neck of the giant aneurysm could not be crossed using other catheters,” said Dr. John Barr.

Yossi Mazel, CEO of the Petach Tikva-based medical device company added, “This first-in-human case in the US together with other cases done in Israel and Europe, has demonstrated the potential of our steerable microcatheter to access torturous anatomies. He concluded, “This feature allows successful endovascular treatments in most complex situations and demonstrates how our catheter can ease access and intra vascular navigation.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”